NCT04620187 2026-02-24
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
Dana-Farber Cancer Institute
Peking Union Medical College
Dana-Farber Cancer Institute
Canadian Cancer Trials Group
Actuate Therapeutics Inc.
Fox Chase Cancer Center
National Cancer Institute (NCI)